(NASDAQ: GANX) Gain Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.37%.
Gain Therapeutics's earnings in 2026 is -$20,161,099.On average, 7 Wall Street analysts forecast GANX's earnings for 2026 to be -$26,190,007, with the lowest GANX earnings forecast at -$32,703,715, and the highest GANX earnings forecast at -$22,177,022. On average, 6 Wall Street analysts forecast GANX's earnings for 2027 to be -$27,478,387, with the lowest GANX earnings forecast at -$30,676,102, and the highest GANX earnings forecast at -$20,846,401.
In 2028, GANX is forecast to generate -$35,115,731 in earnings, with the lowest earnings forecast at -$39,327,253 and the highest earnings forecast at -$30,160,750.